US20040248793A1 - Stabilised solid compositions of factor VII polypeptides - Google Patents

Stabilised solid compositions of factor VII polypeptides Download PDF

Info

Publication number
US20040248793A1
US20040248793A1 US10/609,780 US60978003A US2004248793A1 US 20040248793 A1 US20040248793 A1 US 20040248793A1 US 60978003 A US60978003 A US 60978003A US 2004248793 A1 US2004248793 A1 US 2004248793A1
Authority
US
United States
Prior art keywords
fvii
factor vii
composition
composition according
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/609,780
Other languages
English (en)
Inventor
Michael Jensen
Birthe Hansen
Troels Kornfelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34178323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040248793(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/609,780 priority Critical patent/US20040248793A1/en
Application filed by Individual filed Critical Individual
Publication of US20040248793A1 publication Critical patent/US20040248793A1/en
Assigned to NOVO NORDISK HEALTHCARE A/G reassignment NOVO NORDISK HEALTHCARE A/G ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KORNFELT, TROELS, HANSEN, BIRTHE LYKKEGAARD, JENSEN, MICHAEL BECH
Priority to US11/526,503 priority patent/US8299029B2/en
Priority to US13/573,310 priority patent/US8729022B2/en
Priority to US14/186,145 priority patent/US20140178356A1/en
Priority to US14/823,573 priority patent/US20150343064A1/en
Priority to US15/133,654 priority patent/US20160228553A1/en
Priority to US15/410,342 priority patent/US20170128550A1/en
Priority to US15/819,639 priority patent/US20180085439A1/en
Priority to US16/164,585 priority patent/US20190111118A1/en
Priority to US16/507,115 priority patent/US20190328851A1/en
Priority to US16/862,623 priority patent/US20200254072A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Definitions

  • the present invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
  • Factor VII is a polypeptide involved in the blood clotting process.
  • Factor VIIa can be made by recombinant techniques (rFVIIa) and is widely used as a pro-haemostatic agent.
  • Factor VII human wild-type
  • rFVIIa offers today a rapid and highly effective pro-haemostatic response in haemophilic individuals experiencing bleeding.
  • rFVIIa can be used for treating haemophilic individuals that cannot be treated with other coagulation factor products due to antibody formation.
  • individuals suffering from Factor VII deficiency or individuals having a normal coagulation system but still experiencing excessive bleeding can be treated successfully with rFVIIa.
  • the medicament needs to be effective, safe and lead to good patient compliance.
  • the medicament may be formulated for parenteral administration using pharmaceutically acceptable excipients, which will have to meet with the approval of various world-wide medical regulatory agencies.
  • parenteral administration it is highly desirable that the formulation is approximately isotonic and that the pH of the formulation is in a physiologically suitable range upon injection/infusion, otherwise it may result in pain and discomfort for the patient.
  • the safety may directly be related to the physical and chemical stability of the polypeptide.
  • Factor VII or a Factor VII-related polypeptide is susceptible to physical degradation, including denaturation and aggregation such as the formation of soluble or insoluble aggregates in the form of dimers, oligomers and polymers, or to chemical degradation, including for example, hydrolysis, deamidation and oxidation.
  • the said physical and chemical instability may lead to loss of activity of the Factor VII polypeptide, formation of toxic and immunogenic degradation products, serious risk of introducing thrombosis upon injection of the degraded Factor VII polypeptides, clogging of needles used for injections and risk of non-homogeneity, to name just a few.
  • compositions comprising Factor VII polypeptides that is stabilised against physical and chemical degradation.
  • compositions comprising Factor VII polypeptides need to be stabilised so as allowing storage and handling at ambient temperatures.
  • the instability of polypeptides relates to several parameters and it is impossible to predict the proper manner of stabilising a Factor VIIa or a Factor VII-related polypeptide.
  • One approach of stabilising a protein relates to removal of water from the protein, e.g. such as providing the protein in the form of a lyophilised cake, the final matter obtained in a freeze-drying process.
  • the freeze-drying process itself is also harmful to proteins; during freeze-drying, the protein solution is first cooled until adequately frozen and bulk water in the protein solution will form ice at this stage. The protein is hereby prone to freeze-induced stress resulting in deformation and precipitation.
  • the so-called primary drying stage the ice sublimes and in the secondary drying stage, adsorbed or bound water is removed under elevated temperatures. During this water removal, the proteins may loose their proper conformation that is provided mainly through hydrogen bonding.
  • the polypeptide solution needs to be supplemented with sufficient amounts of proper excipients with cryoprotectant and/or lyoprotectant properties so as to protect the protein from freeze-induced stress and/or stress during removal of water, respectively.
  • an essential feature relates to the properties of the lyophilised cake. It needs to have good properties as to its form and structure, i.e. it should not collapse in that such collapsed cakes can be hard or even impossible to dissolve (reconstitute) before use. Conversely, the physical structure of the lyophilised cake may not be too loosen and soft. Therefore, one or more so-called bulking agents are added to the protein solution before freeze-drying.
  • U.S. 20010031721 A1 (American Home Products) concerns highly concentrated, lyophilised, and liquid Factor IX formulations.
  • WO 97/26909 (Genetics Institute) concerns lyophilised preparations of Factor IX suitable for storage and administration.
  • the preparations may comprise sucrose or mannitol as a cryoprotectant.
  • WO 95/28954 (Genetics Institute) concerns preparations of Factor IX suitable for storage and administration.
  • the preparations may comprise sucrose as a cryoprotectant.
  • Factor VII polypeptides can be provided in a composition that is sufficient stable so as to allow for storage at room temperature for about at least 8 months.
  • the investigators have found that the stabilisation relates to the proper combining of some pharmaceutically acceptable excipients.
  • the present invention relates in a first aspect to stabilised compositions that have a moisture content of not more than about 3% and comprises a Factor VII polypeptide and at least one stability agent selected from the group consisting of a) to e):
  • the invention relates to a method of preparing a stable Factor VII polypeptide comprising the steps of:
  • a still further aspect of the invention relates to the use of Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-responsive syndrome, said medicament comprising a composition comprising;
  • said composition having a moisture content of not more than about 3%.
  • the invention relates to administering said Factor VII polypeptides for treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a composition comprising a Factor VII polypeptide and at least one stability agent selected from the group consisting of
  • composition having a moisture content of not more than about 3%.
  • the present invention relates to storage-stable compositions comprising Factor VII polypeptides.
  • the compositions can be stored at room temperature for an extended period of time without causing substantial degradation of the Factor VII polypeptide.
  • room temperature is meant the ambient temperature inside a room; it normally ranges from about 5° C. to about 40° C., such as from about 10° C. to 30° C., or 15° C. to 25° C.
  • the present investigators have provided stabilised compositions comprising Factor VII polypeptides, thus allowing the compositions to be stored at room temperature for an extended period of time such as at least about 8 months.
  • the stabilised compositions need not to be stored at cooled conditions, such as between 2 and 8° C.
  • the present invention also concerns storage-stable compositions that are stable for at least about 8 months upon storage at about 30° C.
  • the composition is preferably stored in the dark.
  • the present invention makes it possible to store such compositions at room temperature without increasing the risk of adverse events to the patient administering such compositions.
  • the improved storage-stability will also result in reduced cost in that no special cooled conditions are required upon storage, further resulting in more convenient handling of the composition by the user.
  • Factor VII polypeptide is denoted to mean any Factor VII polypeptide that is effective in preventing or treating bleeding. This includes Factor VII polypeptides derived from blood or plasma, or produced by recombinant means.
  • Fractor VII polypeptide encompasses, without limitation, Factor VII, as well as Factor VII-related polypeptides.
  • the term “Factor VII” is intended to encompass, without limitation, polypeptides having the amino acid sequence 1-406 of wild-type human Factor VII (as disclosed in U.S. Pat. No. 4,784,950), as well as wild-type Factor VII derived from other species, such as, e.g., bovine, porcine, canine, murine, and salmon, said Factor VII derived from blood or plasma, or produced by recombinant means. It further encompasses natural allelic variations of Factor VII that may exist and occur from one individual to another.
  • Factor VII is also intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa. Typically, Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa.
  • Factor VII-related polypeptides include without limitation polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids.
  • Factor VII-related polypeptides having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75%, more preferably at least about 100%, more preferably at least about 110%, more preferably at least about 120%, and most preferably at least about 130% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described in the present specification.
  • the Factor VII polypeptides are Factor VII-related polypeptides, in particular variants, wherein the ratio between the activity of said Factor VII polypeptide and the activity of native human Factor VIIa (wild-type FVIIa) is at least about 1.25 when tested in the “In Vitro Hydrolysis Assay” (see Example 9, below); in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0.
  • the Factor VII polypeptides are Factor VII-related polypeptides, in particular variants, wherein the ratio between the activity of said Factor VII polypeptide and the activity of native human Factor VIIa (wild-type FVIIa) is at least about 1.25 when tested in the “In Vitro Proteolysis Assay” (see Example 9, below); in other embodiments, the ratio is at least about 2.0; in further embodiments, the ratio is at least about 4.0; in further embodiments, the ratio is at least about 8.0.
  • Non-limiting examples of Factor VII variants having substantially the same or improved biological activity as wild-type Factor VII include S52A-FVII, S60A-FVII (Lino et al., Arch. Biochem. Biophys.
  • FVII variants as disclosed in PCT/DK02/00189; FVII variants exhibiting increased proteolytic stability as disclosed in WO 02/38162 (Scripps Research Institute); FVII variants having a modified Gla-domain and exhibiting an enhanced membrane binding as disclosed in WO 99/20767 (University of Minnesota); FVII variants as disclosed in WO 01/58935 (Maxygen ApS); FVII variants having increased biological activity compared to wild-type FVIIa as disclosed in WO 01/83725, WO 02/22776, WO 02/077218, PCT/DKO2/00635, Danish patent application PA 2002 01423, Danish patent application PA 2001 01627; WO 02/38162 (Scripps Research Institute); and FVIIa variants with enhanced activity as disclosed in JP 2001061479 (Chemo-Sero-Therapeutic Res Inst.).
  • factor VII or factor VII-related polypeptides include, without limitation, wild-type Factor VII, L305V-FVII, L305V/M306D/D309S-FVII, L3051-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, K157A-FVI
  • Factor VII biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Pat. No. 5,997,864.
  • biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to “Factor VII units” by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity.
  • Factor VIIa biological activity may be quantified by
  • Fractor VII biological activity or “Factor VII activity” is intended to include the ability to generate thrombin; the term also includes the ability to generate thrombin on the surface of activated platelets in the absence of tissue Factor.
  • Example 12 of the present specification describes in detail assays useful for assaying FVII biological activity.
  • stabilising is intended to encompass minimising the formation of aggregates (insoluble and/or soluble) and/or chemical degradation as well as providing maintenance of pH and proper conformation of the protein during storage or production of the compositions so that substantial retention of biological activity and protein stability is maintained. Moreover, stabilising is also denoted to mean lyoprotection and cryoprotection of the protein during production of the compositions at freeze-drying conditions.
  • structural stabilisation or “structural stability” is intended to encompass the ability to form a lyophilised plug or cake with good properties and looks, e.g. such that it does not collapse and is readily dissolved before use.
  • storage-stable is intended to define a product that is stabilised upon storage at temperatures between 5° C.-40° C. and remains within pre-selected product specifications for a suitable time period—often several months.
  • the term “physical stability” of Factor VII polypeptides relates to the formation of insoluble and/or soluble aggregates in the form of dimeric, oligomeric and polymeric forms of Factor VII polypeptides as well as any structural deformation and denaturation of the molecule.
  • the term “chemical stability” is intended to relate to the formation of any chemical change in the Factor VII polypeptides upon storage in dissolved or solid state at accelerated conditions.
  • chemical change in the Factor VII polypeptides upon storage in dissolved or solid state at accelerated conditions.
  • hydrolysis deamidation and oxidation.
  • the sulphur-containing amino acids are prone to oxidation with the formation of the corresponding sulphoxides.
  • cryoprotectants generally include agents, which provide stability to the protein from freezing-induced stresses.
  • cryoprotectants include polyols such as, for example, mannitol, and include saccharides such as, for example, sucrose, as well as including surfactants such as, for example, polysorbate, poloxamer or polyethylene glycol, and the like. Cryoprotectants also contribute to the tonicity of the formulations.
  • lyoprotectant includes agents that provide stability to the protein during water removal upon the drying process of the lyophilisation process. For example by maintaining the proper conformation of the protein.
  • lyoprotectants include saccharides, in particular di- or trisaccharides. Cryoprotectants may also have lyoprotectant effects.
  • agent suitable for keeping the pH in the range of 3 to 9 encompasses those agents that maintain the solution pH in an acceptable range between 3.0 and 9.0.
  • agents capable of keeping the pH within a range of 3 to 9 are the acid form or salts of citric acid, acetic acid, histidine, malic acid, phosphoric acid, tartaric acid, succinic acid, MES, HEPES, PIPES, imidazole, TRIS, lactic acid, glutaric acid and glycylglycine. It is to be understood that a combination of agents, wherein the combination of agents is suitable for maintaining the pH in the above-described range, may also be used in the present invention.
  • lyophilised cake as used herein is denoted to encompass the solid composition obtained upon processing a dissolved or at least a partly dissolved composition under conditions involving at least one step of cooling said dissolved/partly dissolved composition to ice followed by at least one step of vacuum drying.
  • lyophilization and “freeze-drying” encompasses a process during which liquid is removed from a dissolved or at least partly dissolved composition under conditions involving at least one step of cooling the dissolved or partly dissolved solution to ice followed by vacuum drying.
  • Lyophilization or freeze-drying, is the most common process for making solid protein pharmaceuticals. The process consists of two major steps: freezing of a protein solution, and drying of the frozen solid under vacuum. The drying step is further divided into two phases: primary and secondary drying. The primary drying removes the frozen water (sublimation of ice) and the secondary drying removes the non-frozen “bound” water (desorption of water). More detailed analysis of each lyophilization step is provided in, e.g., Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60 (see section 4, page 16 ff.).
  • a composition is freeze-dried by filling into vials, freezing on the shelves of the freeze-dryer, after which a vacuum is established and the shelves heated to implement primary drying (or sublimation of ice). Thereafter, secondary drying (or desorption of sorbed water) takes place at a higher temperature until the completion of the process, i.e., where the composition contains a sufficiently low content of moisture (water).
  • Methods for freeze-drying are generally known in the art, see, for example, Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60. It is within the ordinary skill of the practitioner to optimize the freeze-drying conditions in regard of temperature(s), time(s) at each temperature, and also pressure that is to be used during the process for a specific composition.
  • moisture content is meant to encompass water associated with the product, including, without limitation, water in adsorbed form, such as unfrozen water entrapped in or adsorbed to the frozen solute phase and/or associated with the amorphous phase or adsorbed to the crystalline solid.
  • water content is used interchangeably with “moisture content”.
  • the desired residual moisture level is a function of the duration and the temperature of the secondary drying step.
  • Moisture contents of freeze-dried formulations can be determined by several methods known in the art, such as, for example, loss-on-drying, Karl Fischer titration, thermal gravimetric analysis (TGA), gas chromatography (GC), or near IR (see, e.g. Wang et al, International Journal of Pharmaceutics 203 (2000): 1-60). Methods for determining water contents (moisture contents) are also described in both the European and U.S. Pharmacopoeias. For example, determination of water content can be performed by Karl Fischer coulometric titration as described in the U.S. Pharmacopoeia (USP ⁇ 921, lc>) or the European Phamacopoeia (EP ⁇ 2.5.32>).
  • Moisture content may be defined in terms of the weight of the sample in the vial at the time of analysis (i.e. solids plus the water present—called wet weight basis) or it may be defined in terms where it is corrected for the measured water in the sample (i.e. dry weight basis). In case of freeze-dried products with low moisture contents the two measurements (wet weight basis vs. dry weight basis) yield very similar results. As used herein, moisture contents are defined in terms of the solids plus the water present (i.e., wet weight basis).
  • the term “bulking agent” generally includes agents, which provide good lyophilised cake properties, which form a pharmaceutically elegant product, which help the protein overcome various stresses, shear/freezing for example, associated with lyophilisation processes, and which help to maintain protein activity levels during the freeze-drying process and subsequent storage.
  • Typical examples of bulking agents include mannitol, glycine, sucrose, lactose. These agents may also contribute to the tonicity of the formulations.
  • tonicity modifier is denoted to mean any agent capable of adjusting the tonicity of the composition such that upon dissolving the composition at the time of use, the composition has a tonicity within the physiological range of the blood, peritoneal fluid or other relevant body fluids. Obviously, the tonicity may also depend on whether the reconstitution solution comprises tonicity-modifying agents.
  • surfactants generally include those agents, which protect the protein from air/solution interface-induced stresses and solution/surface induced-stresses.
  • Suitable surfactants may include e.g. polysorbates, polyoxyethylene alkyl ethers such as Brij 35®, or poloxamer such as Tween 20, Tween 80, or poloxamer 188.
  • Preferred detergents are poloxamers, e.g. Poloxamer 188, Poloxamer 407; polyoxyethylene alkyl ethers, e.g. Brij 35®, Cremophor A25, Sympatens ALM/230; and polysorbates/Tweens, e.g. Polysorbate 20, Polysorbate 80. More preferred are Poloxamers, e.g. Poloxamer 188, and Tweens, e.g. Tween 20 and Tween 80.
  • the term “initial content” relates to the amount of Factor VII polypeptides added to a composition at the time of preparation.
  • concentration given herein refer to either the concentration in the solution of Factor VII polypeptide before removing the moisture (e.g. before freeze-drying) or in the reconstituted composition, or is referred as % w/w, which then relates to the concentration in the solid composition, e.g. the lyophilised cake.
  • amounts specified are understood to be ⁇ about 10%; thus about 50 mM includes 50 mM ⁇ 5mM, 4% includes 4% ⁇ 0.4%, etc.
  • a proper stability agent includes the combination of at least two groups of pharmaceutically acceptable excipients selected from the group consisting of antioxidants, saccharides and polyols.
  • the saccharides and polyols have lyoprotectant and/or cryoprotectant properties that may be important, at least in part, in the event where the composition is freeze-dried.
  • improved stability may be achieved, in part, by the proper combination of at least two of these groups of excipients.
  • said combination comprises a saccharide (sucrose) or an antioxidant (methionine)
  • the stabilising effect may be even more significant.
  • methionine prevents oxidative degradation of the Factor VII polypeptides.
  • the invention relates to a composition
  • a composition comprising a Factor VII polypeptide and at least one stability agent selected from the group consisting of
  • composition having a moisture content of not more than about 3%.
  • one embodiment of the invention comprises a combination of an antioxidant and mannitol; a second embodiment comprises a combination of methionine and a polyol; another embodiment comprises a combination of a saccharide and mannitol; in still another embodiment, the composition comprises a combination of sucrose and a polyol; and finally in another suitable embodiment, the composition comprises methionine.
  • the stabilising agent according to the invention includes combining at least two groups of pharmaceutically acceptable excipients.
  • the stabilising agent further comprises a third group of excipients.
  • the combination of an antioxidant and mannitol further comprises a saccharide.
  • the combination of methionine and a polyol further comprises a saccharide.
  • the combination of a saccharide and mannitol further comprises an antioxidant and the combination of sucrose and a polyol further comprises an antioxidant.
  • the composition of the invention comprises mannitol and sucrose; in another embodiment, the composition comprises mannitol, sucrose and methionine; in another embodiment, the composition comprises mannitol and trehalose; in another embodiment, the composition comprises mannitol, trehalose and methionine
  • the Factor VII polypeptide is meant to encompass the polypeptides as described above.
  • the Factor VII polypeptide is selected from the group consisting of Human Factor VIIa, Recombinant Human Factor VIIa and a Factor VII Sequence Variant.
  • the Factor VII Polypeptide is Human Factor VIIa or Recombinant Human Factor VIIa or a Factor VII-related polypeptide wherein the ratio between the activity of said Factor VII-related polypeptide and wild-type Factor VII is at least 1.25 when tested in one or more of the “In Vitro Proteolysis Assay” and the “in Vitro Hydrolysis Assay” as described in the present specification.
  • the moisture content should be limited.
  • the Factor VII polypeptides when provided in bulk, may be provided in solid or liquid form.
  • further processing of the bulk proteins for the manufacturing of compositions requires the steps of adding suitable excipients and removing the liquid from the bulk, said addition of excipients may be carried out before or after removing the liquid.
  • One such mean for removing liquid from a protein relates to freeze-drying. Therefore, in a preferred embodiment of the present invention, the composition is in the form of a lyophilised cake.
  • the present invention does not preclude other processes that are suitable for removing the liquid from the bulk polypeptide so as to achieve a solid composition with moisture content of not more than about 3% w/w.
  • the moisture content is preferably not more than about 2.5% w/w, preferably not more than about 2% w/w, most preferably not more than about 1.5% w/w.
  • the invention relates, in part, to limiting the degradation of Factor VII polypeptides during preparation, e.g. during admixing of excipients and removing of liquid so as to achieve a solid composition with moisture content of the most 3% w/w, and to limiting said degradation from the time of manufacturing the solid composition until the time of use, e.g. until the time when the composition is to be administered by a patient.
  • the pH should be kept in the pH range within 3 to 9 when dissolved in aqueous solvent, such as, e.g., pure water or aqueous buffer. That is to say that the pH in the polypeptide solution at the time before removing the moisture content, e.g. before freeze-drying, should be kept within a pH of about 3 to about 9.
  • this pH range is also within the desired physiological range, thereby causing no harm to the user upon administering the composition by parenteral means.
  • the pH of the solution is from about 4.0 to about 9.0, such as 4.0 to 8.0, 4.0 to 7.5, 4.0 to 7.0, 4.5 to 7.0, 4.5 to 6.8, 4.5 to 6.5, 5.0 to 7.0, 5.0 to 6.5, 5.0 to 6.0, 5.5 to 6.5, or about 5.5 to about 6.0 such as about 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0.
  • interesting embodiments of the invention further comprises an agent suitable for keeping the pH of said composition in the range of 3 to 9 when dissolved in aqueous solution (e.g. water).
  • aqueous solution e.g. water
  • the agent suitable for keeping the pH in the range of 3 to 9 is selected from the group consisting of acid or salts of citric acid, acetic acid, histidine, malic acid, phosphoric acid, tartaric acid, succinic acid, MES, HEPES, imidazole, TRIS, lactic acid, glutaric acid, PIPES and glycylglycine.
  • the suitable agent for keeping the pH in the range of 3 to 9 may also be a mixture of at least two such listed agents, wherein the mixture is able to provide a pH value in the specified range.
  • the concentration of the suitable agents is in the range of from about 0.1 mM to 100 mM; from about 0.2 mM to 50 mM; from about 0.5 mM to 25 mM; from about 1 mM to 20 mM; or from about 1 mM to 10 mM.
  • compositions with low contents of oxidised forms and aggregates upon termination of the manufacturing process i.e. upon termination of the freeze-drying process, by combining proper amounts of mannitol (a polyol), sucrose (a saccharide) and an antioxidant (methionine).
  • mannitol a polyol
  • sucrose a saccharide
  • antioxidant methionine
  • the compositions are stabilised upon termination of the freeze-drying such that less than 5% w/w, such as less than 4, 3 or 2% w/w of the initial content of Factor VII polypeptide is converted into its oxidised forms.
  • the initial content of said Factor VII polypeptide being the amount added to the composition upon preparation of the composition before the freeze-drying step.
  • less than 5% w/w, such as less than 4.0%, 3.0%, 2.5%, 2%, 1.5%, or less than 1% w/w of the initial content of Factor VII polypeptide is recovered as aggregate forms, as determined by conventional analytical methods (such as, for example, as described in the Examples of the present application).
  • suitable compositions have a limited increase in the content of oxidised forms upon storage for at least 8 months at ambient conditions. That is to say that in still more interesting embodiments, the composition is stable such that no more than about 6% w/w of the initial content of Factor VII polypeptide is additionally degraded into oxidised forms upon storage of the composition for 8 months at 30° C. after termination of the manufacturing process, e.g. freeze-drying process. In further suitable embodiments thereof, not more than about 5, 4, 3, 2, or 1.5% w/w or of the Factor VII polypeptide is additionally converted into oxidised forms, as calculated from the time of termination of the manufacturing process until 8 months of storage at 30° C.
  • compositions are stable such that not more than about 5% (4, 3, 2, or 1.5%) w/w of the initial content of Factor VII polypeptide is converted to oxidised forms upon storage of said composition at 30° C. for 8 months.
  • the initial content relates to the amount of Factor VII polypeptide added to the composition upon preparation of the composition before the freeze-drying step.
  • the degradation of Factor VII polypeptides by the aggregation pathway may also be regarded as an essential stability indicating parameter.
  • compositions that are stable such that not more than about 5% w/w of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30° C. for 8 months.
  • the initial content of said Factor VII polypeptide being the amount added to the composition upon preparation of the composition before the freeze-drying step.
  • the composition is stable such that not more than about 4.0%, 3.0% w/w, such as 2.5, 2.0, 1.5, or 1.0% w/w, of the initial content of Factor VII polypeptide is converted to aggregates upon storage of said composition at 30° C. for 8 months.
  • compositions of the invention have low contents of oxidised forms and aggregates upon termination of the manufacturing process, i.e. upon termination of the freeze-drying process, and thus the compositions according to the invention are characterised by having a low initial content of oxidised forms and aggregates before being subjected to storage, e.g.
  • compositions of the invention are storage-stable, e.g. less than 10% w/w, such as 6%, 5%, 4%, 3%, 2%, or 1.5% w/w of the initial contents of Factor VII polypeptide is converted into an oxidised form, and less than 5% w/w, such as 4%, 3%, 2.5%, 2%, 1.5%, or 1% w/w is converted into a dimeric or higher-order polymeric form upon storage at 30° C. for at least 8 months in the dark.
  • the excipients should be selected from the group of saccharides, polyols and antioxidants in that the saccharides and polyols exhibit lyoprotectant and/or cryoprotectant properties.
  • the saccharides of interest are di- and tri-saccharides and polysaccharides such that the saccharides may be selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans.
  • the polyol is selected from the group consisting of mannitol, sorbitol and xylitol.
  • the antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, gluthatione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and gluthatione.
  • the saccharide and polyol excipients may also be a mixture of at least two such listed agents.
  • the saccharide excipient used is a combination of at least two di-, tri- and/or polysaccharides, such as, for example, sucrose in combination with cyclodextrin, trehalose in combination with cyclodextrin, sucrose in combination with dextran, or sucrose in combination with lactose.
  • the polyol excipient used is a combination of at least two polyols, such as, for example, mannitol in combination with sorbitol, mannitol in combination with xylitol, or sorbitol in combination with xylitol.
  • the antioxidant excipient used is a combination of at least two antioxidants, such as, for example, methionine in combination with one or more of homocysteine, cysteine, cystathionine, gluthatione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and gluthatione.
  • the polyols are to be present in an amount ranging from about 5% w/w to about 90% w/w.
  • the amount of the polyol is to be present in a range from about 18% w/w to about 88% w/w, such as from about 18% w/w to about 83% w/w, 25% to 80%, 30% to 65%, 30% to 80%, 40% to 80%, 50% to 80%, 30% to 75%, 40% to 75%, 50% to 75%, or from about 50% to about 70% w/w.
  • the polyol are to be present in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, 5 mg/ml to 55 mg/ml, 8 to 45 mg/ml, 10 to 40 mg/ml, 10 to 30 mg/ml, or from about 2 to 45 mg/ml, 5 mg/ml to 45 mg/ml, 5 to 35 mg/ml, 5 to 25 mg/ml, 5 to 20 mg/ml, 20 to 40 mg/ml, or such as from about 20 to 30 mg/ml,
  • the saccharide is to be present in the composition in an amount ranging from about 0 to about 85% w/w. In further interesting embodiments thereof, the amount ranges from about 3% w/w to about 80% w/w, such as from about 7% w/w to about 75% w/w, 10% to 70%, 10% to 50%, 20% to 50%, 10% to 40%, or from about 10% w/w to about 35% w/w.
  • the saccharide should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as from about 5 to 20 mg/ml.
  • antioxidants should range between from about 0.05 to 10 mg/ml, such as from about 0.1 to 5 mg/ml, 0.1 mg/ml to 2.5 mg/ml, 0.1 to 2 mg/ml, or from about 0.1 to 1 mg/ml.
  • the ratio between the polyol and the saccharide needs to be proper adjusted.
  • said polyol is in a weight ratio relative to said saccharide ranging from about 100:1 to 1:50.
  • said weight ratio is from about 50:1 to 1:10, more preferably from about 20:1 to 1:5.
  • the weight ratio relates to ranges from about 10:1 to 1:2, and from about 6:1 to 1:2.
  • very suitable embodiments relate to those wherein said sugar alcohol is in a weight ratio relative to said saccharide ranging from about 4:1 to 1:1, such as from about 4:1 to 3:2 or from about 1:1 to 3:2.
  • the polyol is mannitol and in still further embodiments the saccharide is sucrose. Moreover, in still further embodiments the antioxidant is methionine.
  • compositions may further be suitable formulated by incorporating other pharmaceutically acceptable excipients so as to achieve compositions acceptable for parenteral administration, in particular to intravenous administration.
  • excipients includes pharmaceutical acceptable reagents to provide good lyophilised cake properties (bulking agents) as well as provide lyoprotection and cryoprotection of the protein, maintenance of pH, maintenance of acceptable tonicity as well as proper conformation of the protein during storage so that substantial retention of biological activity and protein stability is maintained.
  • the compositions further comprise a tonicity modifier.
  • the tonicity modifier may be selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride and calcium chloride.
  • suitable tonicity modifiers are not precluded.
  • compositions may comprise much higher concentrations of the tonicity-modifying agent as long as the composition is made isotonic or close to isotonic prior to use (e.g., slightly hypertonic or hypotonic), for example bulk compositions need not to be isotonic with the physiological range.
  • compositions comprising a Factor VII polypeptide can be obtained by the addition of surfactants.
  • a surfactant being selected from the group consisting of polysorbates, e.g. Tween®, such as polysorbate 20 or 80; polyoxyethylene alkyl ethers, e.g., polyoxyl 23 lauryl ether (Brij 35®) or poloxamers, such as poloxamer 188 (e.g.
  • Pluronic® or poloxamer 407 e.g., Lutrol®
  • poloxamer 407 e.g., Lutrol®
  • PEG polyethyleneglycols
  • the surfactants are added in an amount of from 0.005 to 5 mg/ml. Preferred amounts are from 0.01 to 3 mg/ml, more preferred from 0.01 to 0.3 mg/ml for Tween 20 and/or Tween 80 and from 0.05 to 3.0 mg/ml for Poloxamer 188.
  • the composition further comprises other pharmaceutical excipients acting as bulking agent. That is to say that bulking agents other than mannitol are included in the compositions. In particular, bulking agents are included in compositions prepared by freeze-drying.
  • Initial contents of Factor VII polypeptide in the composition is preferably from about 0.6 mg/ml to about 10.0 mg/ml, such as from about 0.6 mg/ml to about 6.0 mg/ml, from about 0.6 mg/ml to about 5 mg/ml, or from about 0.6 mg/ml to about 4 mg/ml.
  • the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, methionine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises Factor VII polypeptide, Mannitol, Sucrose, Histidine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises: Factor VII polypeptide, Mannitol, Sucrose, methionine, Histidine, and Tween 80, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises Factor VII polypeptide, Mannitol, Sucrose, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises Factor VII polypeptide, Mannitol, Sucrose, methionine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises Factor VII polypeptide, Mannitol, Sucrose, Histidine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • the composition comprises Factor VII polypeptide, Mannitol, Sucrose, Histidine, methionine, and Poloxamer 188, has a moisture content of not more than about 3%, and has a pH in the range of 5.0 to 7.0 when the composition is dissolved in water.
  • the composition further comprises one or more components selected from the list of: CaCl2, NaCl, and Glycylglycine.
  • the Factor VII polypeptide is human Factor VIIa.
  • compositions are as shown in Table A below.
  • compositions are as shown in Table B below TABLE B Formulation Formulation Formulation Formulation Formulation Compound E F G H FVIIa 1.0 mg/ml 1.0 mg/ml 1.0 mg/ml 1.0 mg/ml polypeptide CaCl2 ⁇ 2H2O 10 mM 10 mM 10 mM NaCl 39 mM 39 mM 39 mM 39 mM Glycylglycine 10 mM 10 mM 10 mM 10 mM Mannitol 25 mg/ml 25 mg/ml 25 mg/ml 25 mg/ml 25 mg/ml Sucrose 10 mg/ml 10 mg/ml 10 mg/ml 10 mg/ml Methionine 0.5 mg/ml 0.5 mg/ml 0.5 mg/ml 0.5 mg/ml Tween 80 0.1 mg/ml — 0.1 mg/ml — Poloxamer 188 — 1.0 mg/ml 1.0 mg/ml L-Hist
  • compositions contains the excipients, and amounts thereof, listed in Table B above, but are formulated at pH 5.9.
  • compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.8.
  • compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5 7.
  • compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5 6.
  • compositions contains excipients, and amounts thereof, as listed in Table B above, but are formulated at pH 5.5.
  • the present investigators have provided a method for stabilising Factor VII polypeptides by providing the proteins in solid compositions comprising selected pharmaceutically acceptable excipients, of which it is important to include a stabilising agent.
  • a stabilising agent is composed of a combination of at least two groups of excipients selected from excipients being saccharides, polyols or antioxidants.
  • saccharides saccharides
  • antioxidants methionine
  • a further aspect of the invention relates to a method of preparing a stable Factor VII polypeptide.
  • the method comprises the steps of:
  • the method comprises that said antioxidant is selected from the group consisting of homocysteine, cysteine, cystathionine, methionine, gluthatione, and peptides containing any one of homocysteine, cysteine, cystathionine, methionine and gluthatione.
  • the antioxidant is methionine.
  • said saccharide is selected from the group consisting of sucrose, dextrose, lactose, maltose, trehalose, cyclodextrins, maltodextrins and dextrans.
  • the polyol is mannitol and the saccharide is sucrose.
  • the antioxidant is methionine.
  • the content of the saccharide and optionally the content of the antioxidant in said solution i) should be adjusted so as to achieve superior stabilised Factor VII polypeptides.
  • the saccharide should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as from about 5 to 20 mg/ml.
  • the polyol should be in an amount ranging from about 0.5 to 75 mg/ml, such as from about 2 to 60 mg/ml, from about 5 mg/ml to 55 mg/ml, from about 8 to 45 mg/ml, from about 10 to 40 mg/ml, from about 10 to 30 mg/ml, or from about 2 to 45 mg/ml, from about 5 mg/ml to 45 mg/ml, from about 5 to 35 mg/ml, from about 5 to 25 mg/ml, such as from about 5 to 20 mg/ml.
  • the antioxidant should be provided in an amount ranging from about 0.05 to 10 mg/ml, preferably from about 0.1 to 5 mg/ml, more preferably from about 0.1 mg/ml to 2.5 mg/ml, even more preferably from about 0.1 to 2 mg/ml, most preferably from about 0.1 to 1 mg/ml.
  • the method for preparing a stable Factor VII polypeptide comprises freeze-drying.
  • the freeze-drying relates to a process, wherein the solution comprising said Factor VII polypeptide is filled into lyophilisation vials or the like.
  • Said Factor VII polypeptide may optionally be subjected to sterile filtration before start of freeze-drying. Cooling is applied to the shelves of the freeze-drier in order to freeze the vials and the solution below critical product temperatures. Water is removed by introducing vacuum and condensation of water vapour on the ice-condenser of the freeze-drier.
  • the vials are closed and capped. Manufacturing is finalised and the composition is now in a form of a lyophilised cake.
  • compositions when administered to a patient by injectable means, need to be reconstituted in a suitable liquid before use. They may also be reconstituted for other purposes, e.g. for reformulation into other pharmaceutical compositions. However, the present invention does not preclude that the compositions may be administered to a patient in their solid form.
  • compositions are reconstituted using an acceptable, preferably sterile, diluent or carrier, preferably an aqueous carrier.
  • aqueous carriers may be used, e.g., water (e.g. Water for Injection/WFI), buffered water, saline (e.g. 0.4% saline), glycine (e.g. 0.3% glycine), histidine, and the like.
  • the reconstitution diluent may also contain one or more salts, such as a calcium salt (e.g. CaCl2) or a combination of a sodium salt and a calcium salt (e.g. NaCl and CaCl2).
  • compositions are intended for parenteral administration for prophylactic and/or therapeutic treatment.
  • the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutanously, or intramuscularly, or they are administered by way of continuous or pulsative infusion.
  • a still further aspect of the invention relates to the use of the solid stabilised composition for the preparation of a medicament for treating a Factor VII-responsive syndrome.
  • one aspect of the invention relates to the use of Factor VII polypeptide for the preparation of a medicament for treating a Factor VII-responsive syndrome, said medicament comprising a composition comprising;
  • composition having a moisture content of not more than about 3%.
  • the invention relates to administering said stabilised Factor VII polypeptide to a patient for treating a Factor VII-responsive syndrome.
  • the invention relates to a method of treating a Factor VII-responsive syndrome comprising administering to a subject in need thereof an effective amount of a composition comprising a Factor VII polypeptide, and at least one stability agent selected from the group consisting of
  • composition having a moisture content of not more than about 3%.
  • said Factor VII-responsive syndrome is haemophilia A, haemophilia B, Factor XI deficiency, Factor VII deficiency, thrombocytopenia, von Willebrand's disease, presence of a clotting Factor inhibitor, surgery or trauma. Additionally, Factor VII-responsive syndrome may be associated with anticoagulant therapy.
  • the composition is in solid form. Accordingly, in a suitable embodiment the medicament should be suitable for being dissolved, which allows for parenteral administration of the medicament.
  • it comprises the step of dissolving the composition in a suitable liquid prior to the administering step.
  • compositions comprising Factor VII polypeptides and prepared according to Example 2 are shown. Typical excipients and their typical amounts are shown.
  • Table 1 shows the concentration of active ingredients and excipients in the event where the composition is in liquid form, that is, in the composition before finalising the manufacturing (e.g. finalising the freeze-drying), or in the reconstituted solution.
  • Table 2 shows the concentration of active ingredient and excipients in the event where the composition is in solid form, i.e. in freeze-dried form.
  • Table 1 Compositions, content of excipients in solution. Content (mg/ml) in liquid Main Function: Excipients: composition Active Ingredient rFVIIa 0.6-5 Tonicity modifier Sodium Chloride 0-4 Tonicity modifier/ Calcium Chloride, 2H 2 0 1-7 stabiliser Buffering agent Glycylglycine 1.32 (0-1.5) Surfactant Polysorbate 80 0.05-2 Bulking Agent/ Mannitol 10-40 Cryoprotectant/ Lyoprotectant Bulking Agent/ Sucrose 10-40 Cryoprotectant/ Lyoprotectant Antioxidant Methionine 0-1.0 pH 5-6
  • compositions content of excipients in freeze-dried form.
  • Content (% w/w) in solid Main Function Excipients: composition Active Ingredient rFVIIa 0.6-19 Tonicity modifier Sodium Chloride 0-15 Tonicity modifier/ Calcium Chloride, 2H 2 0 1.0 to 24.0 stabiliser Buffering agent Glycylglycine 0-6.0 Surfactant Polysorbate 80 0.05-8.0 Bulking Agent/ Mannitol 13-76 Cryoprotectant/ Lyoprotectant Bulking Agent/ Sucrose 13-76 Cryoprotetant/ Lyoprotectant Antioxidant Methionine 0-4.2 pH 5-6
  • compositions were prepared from a purified bulk solution. Excipients were added, and the solution was diluted to the desired concentration of rFVIIa. The resulting solution was sterile filtered using a sterilised membrane filter (0.2 micron pore size or equivalent) and filled into sterile glass vials. The vials were freeze-dried, stoppered and sealed with aluminium flip-off type caps.
  • compositions 1-19 comprising various amounts of sodium chloride, mannitol, sucrose and methionine and with various pH values were prepared according to the process described in Example 2.
  • the compositions comprised fixed concentrations of Factor VII (1.0 mg/ml), Calcium Chloride, 2H 2 O (1.47 mg/ml), Glycylglycine (1.32 mg/ml) and Polysorbate 80 (1.0 mg/ml).
  • Factor VII 1.0 mg/ml
  • Calcium Chloride 2H 2 O (1.47 mg/ml
  • Glycylglycine (1.32 mg/ml
  • Polysorbate 80 1.0 mg/ml
  • HPLC Column 4.5 ⁇ 250 mm column packed with butylbonded silica with a particle size of 5 ⁇ m and pore size 300 ⁇ . Column temperature: 70° C.
  • Eluent A water 99.9% v/v and trifluoracetic acid 0.1% v/v.
  • Eluent B acetonitrile 80% v/v. trifluoracetic acid 0.09% v/v and water 19.91% v/v.
  • the column was eluted with a linear gradient from X% B to (X+13)% B in 30 minutes. Flow rate: 1.0 ml/min. Detection: 214 nm.
  • the oxidised forms are methionine sulfoxides of Factor VII Polypeptides.
  • FVII the two main derivatives of FVII are Met(O)298 FVII and Met(O)306 FVII.
  • the content of oxidised forms is expressed as the percentage of the initial amount of Factor VII in the composition upon preparation that is recovered as oxidised forms of Factor VII.
  • GP-HPLC was run on a Waters Protein Pak 300 SW column. 7.5 ⁇ 300 mm. using 0.2 M ammoniumsulfat pH 7.0 containing 5% isopropanol as the mobile phase. Flow rate: 0.5 ml/min and detection: 215 nm.
  • the content of aggregates is expressed as the percentage of the initial amount of Factor VII in the composition upon preparation that is recovered as dimeric, oligomeric and polymeric forms of Factor VII.
  • compositions 1-19 of Example 3 were analysed by method A (Example 4) for content of oxidised forms upon termination of the freeze-drying and upon 2 and 8 months of storage at 30° C. TABLE 4 Content of oxidised forms and increase thereof upon storage for 8 months. % of the initial content of Factor VIIa recovered as oxidised forms.
  • Composition increase 0-8 No 0 2 8 months 1 2.5 3.5 4.8 2.3 2 2.7 3 6.1 3.4 3 2.3 3.7 7 4.7 4 2.7 5.5 12 9.3 5 2.6 3.6 5.3 2.7 6 2.7 3.3 5.8 3.1 7 3 3.5 5.2 2.2 8 2.3 2.9 3.4 1.1 9 1.6 1.5 1.7 0.1 10 1.7 1.7 2.1 0.4 11 1.7 1.8 2.5 0.8 12 1.6 1.6 1.9 0.3 13 1.7 1.6 1.7 0 14 1.6 1.5 1.6 0 15 1.6 1.5 1.8 0.2 16 1.7 1.6 1.8 0.1 17 1.7 1.6 n.a. n.a. 18 1.7 1.6 1.9 0.2 19 1.7 1.6 1.8 0.1
  • compositions comprising methionine are more stable towards oxidative degradation.
  • compositions 1-19 of Example 3 were analysed by method B (Example 4) for content of aggregates upon termination of the freeze-drying and upon 2 and 8 months of storage at 30° C. TABLE 5 Content of aggregates and their increase upon storage for 8 months. % of the initial content of Factor VIIa recovered as aggregates.
  • Composition increase 0-8 No 0 2 8 months 1 0.7 0.8 0.9 0.2 2 1 2 2.9 1.9 3 1.5 2.5 3.5 2 4 1.1 2.1 3.1 2 5 0.8 1 1.1 0.3 6 0.8 1.2 1.1 0.3 7 0.9 1 0.9 0 8 0.9 1 1.2 0.3 9 0.9 1 1.1 0.2 10 0.8 1.7 2.5 1.7 11 1 1.2 1.5 0.5 12 1.3 2 2.8 1.5 13 0.7 0.8 0.9 0.2 14 1 1.7 1.4 0.4 15 1.1 1.4 1.5 0.4 16 0.8 0.9 1 0.2 17 0.9 1.1 n.a. n.a. 18 0.8 1 1.5 0.7 19 1 1 1.1 0.1 0.1
  • composition A comprising polyol and saccharide as listed in the table below was prepared according to the process described in Example 2.
  • the composition further comprised Factor VIIa (1.0 mg/ml), calcium chloride 2 H2O (1.47 mg/ml), glycylglycine (1.32 mg/ml) and polysorbate 80 (0.7 mg/ml). pH was 5.0.
  • Composition A was analysed by method B (Example 4) for content of aggregates upon termination of the freeze-drying and upon 1 and 2 months of storage at 30° C.
  • the table lists the % of the initial content of Factor VIIa recovered as aggregates: TABLE 6 % of the initial content of Factor VIIa recovered as aggregates.
  • formulations B and C which contain mannitol, sucrose, and methionine are more stable—i.e. shows a slower increase in contents of dimer and oligomer forms and oxidised forms.
  • the activities of these formulations are higher as measured after 3 months' storage at 30° C.
  • composition of the formulations was: rFVIIa 1.0 mg/ml CaCl 2 10 mM Glycylglycine 10 mM L-Histidin 10 mM NaCl 39 mM Tween 80 0.07 mg/ml Mannitol 25 mg/ml Sucrose 10 mg/ml
  • a suitable assay for testing for Factor VIIa activity and thereby selecting suitable Factor VIIa variants can be performed as a simple preliminary in vitro test: (the “In Vitro Hydrolysis Assay”).
  • Native (wild-type) Factor VIIa and Factor VIIa variant may be assayed for specific activities. They may also be assayed in parallel to directly compare their specific activities.
  • the assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark).
  • the absorbance at 405 nm is measured continuously in a SpectraMaxTM 340 plate reader (Molecular Devices, USA).
  • the absorbance developed during a 20-minute incubation, after subtraction of the absorbance in a blank well containing no enzyme, is used to calculate the ratio between the activities of variant and wild-type Factor VIIa:
  • Ratio ( A 405 nm Factor VIIa variant)/( A 405 nm Factor VIIa wild-type).
  • Factor VIIa variants with an activity comparable to or higher than native Factor VIIa may be identified, such as, for example, variants where the ratio between the activity of the variant and the activity of native Factor VII (wild-type FVII) is around, versus above 1.0.
  • the activity of Factor VIIa or Factor VIIa variants may also be measured using a physiological substrate such as Factor X, suitably at a concentration of 100-1000 nM, where the Factor Xa generated is measured after the addition of a suitable chromogenic substrate (eg. S-2765) (“the In Vitro Proteolysis Assay”).
  • a physiological substrate such as Factor X
  • a suitable chromogenic substrate eg. S-2765
  • the activity assay may be run at physiological temperature.
  • Factor VIIa Native (wild-type) Factor VIIa and Factor VIIa variant (both hereafter referred to as “Factor VIIa”) are assayed in parallel to directly compare their specific activities.
  • the assay is carried out in a microtiter plate (MaxiSorp, Nunc, Denmark).
  • Factor X cleavage is then stopped by the addition of 50 microL 50 mM Hepes, pH 7.4, containing 0.1 M NaCl, 20 mM EDTA and 1 mg/ml bovine serum albumin.
  • the amount of Factor Xa generated is measured by addition of the chromogenic substrate Z-D-Arg-Gly-Arg-p-nitroanilide (S-2765, Chromogenix, Sweden), final concentration 0.5 mM.
  • the absorbance at 405 nm is measured continuously in a SpectraMaxTM 340 plate reader (Molecular Devices, USA). The absorbance developed during 10 minutes, after subtraction of the absorbance in a blank well containing no FVIIa, is used to calculate the ratio between the proteolytic activities of variant and wild-type Factor VIIa:
  • Ratio ( A 405 nm Factor VIIa variant)/( A 405 nm Factor VIIa wild-type).
  • Factor VIIa variants with an activity comparable to or higher than native Factor VIIa may be identified, such as, for example, variants where the ratio between the activity of the variant and the activity of native Factor VII (wild-type FVII) is around, versus above 1.0.
  • Factor VII or Factor VII-related polypeptides or Factor VII or Factor VII-related polypeptides e.g., variants
  • thrombin The ability of Factor VII or Factor VII-related polypeptides or Factor VII or Factor VII-related polypeptides (e.g., variants) to generate thrombin can be measured in an assay comprising all relevant coagulation Factors and inhibitors at physiological concentrations and activated platelets (as described on p. 543 in Monroe et al. (1997) Brit. J. Haematol. 99, 542-547 which is hereby incorporated as reference).
  • the activity of the Factor VII polypeptides may also be measured using a one-stage clot assay (assay 4) essentially as described in WO 92/15686 or U.S. Pat. No. 5,997,864. Briefly, the sample to be tested is diluted in 50 mM Tris (pH 7.5), 0.1% BSA and 100 gL is incubated with 100 ⁇ L of Factor VII deficient plasma and 200 ⁇ L of thromboplastin C containing 10 mM Ca 2+ . Clotting times are measured and compared to a standard curve using a reference standard or a pool of citrated normal human plasma in serial dilution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
US10/609,780 2002-06-21 2003-06-30 Stabilised solid compositions of factor VII polypeptides Abandoned US20040248793A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/609,780 US20040248793A1 (en) 2002-06-21 2003-06-30 Stabilised solid compositions of factor VII polypeptides
US11/526,503 US8299029B2 (en) 2002-06-21 2006-09-25 Stabilised solid compositions of factor VII polypeptides
US13/573,310 US8729022B2 (en) 2002-06-21 2012-09-10 Stabilised solid compositions of factor VII polypeptides
US14/186,145 US20140178356A1 (en) 2002-06-21 2014-02-21 Stabilised Solid Compositions of Factor VII Polypeptides
US14/823,573 US20150343064A1 (en) 2002-06-21 2015-08-11 Stabilised Solid Compositions of Factor VII Polypeptides
US15/133,654 US20160228553A1 (en) 2002-06-21 2016-04-20 Stabilised Solid Compositions of Factor VII Polypeptides
US15/410,342 US20170128550A1 (en) 2002-06-21 2017-01-19 Stabilised Solid Compositions of Factor VII Polypeptides
US15/819,639 US20180085439A1 (en) 2002-06-21 2017-11-21 Stabilised Solid Compositions of Factor VII Polypeptides
US16/164,585 US20190111118A1 (en) 2002-06-21 2018-10-18 Stabilised Solid Compositions of Factor VII Polypeptides
US16/507,115 US20190328851A1 (en) 2002-06-21 2019-07-10 Stabilised Solid Compositions of Factor VII Polypeptides
US16/862,623 US20200254072A1 (en) 2002-06-21 2020-04-30 Stabilised Solid Compositions of Factor VII Polypeptides

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200200963 2002-06-21
DKPA200200963 2002-06-21
US39415302P 2002-07-03 2002-07-03
PCT/DK2003/000419 WO2004000347A1 (en) 2002-06-21 2003-06-20 Stabilised solid compositions of factor vii polypeptides
US10/609,780 US20040248793A1 (en) 2002-06-21 2003-06-30 Stabilised solid compositions of factor VII polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000419 Continuation WO2004000347A1 (en) 2002-06-21 2003-06-20 Stabilised solid compositions of factor vii polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/526,503 Continuation US8299029B2 (en) 2002-06-21 2006-09-25 Stabilised solid compositions of factor VII polypeptides

Publications (1)

Publication Number Publication Date
US20040248793A1 true US20040248793A1 (en) 2004-12-09

Family

ID=34178323

Family Applications (11)

Application Number Title Priority Date Filing Date
US10/609,780 Abandoned US20040248793A1 (en) 2002-06-21 2003-06-30 Stabilised solid compositions of factor VII polypeptides
US11/526,503 Active 2024-11-16 US8299029B2 (en) 2002-06-21 2006-09-25 Stabilised solid compositions of factor VII polypeptides
US13/573,310 Expired - Lifetime US8729022B2 (en) 2002-06-21 2012-09-10 Stabilised solid compositions of factor VII polypeptides
US14/186,145 Abandoned US20140178356A1 (en) 2002-06-21 2014-02-21 Stabilised Solid Compositions of Factor VII Polypeptides
US14/823,573 Abandoned US20150343064A1 (en) 2002-06-21 2015-08-11 Stabilised Solid Compositions of Factor VII Polypeptides
US15/133,654 Abandoned US20160228553A1 (en) 2002-06-21 2016-04-20 Stabilised Solid Compositions of Factor VII Polypeptides
US15/410,342 Abandoned US20170128550A1 (en) 2002-06-21 2017-01-19 Stabilised Solid Compositions of Factor VII Polypeptides
US15/819,639 Abandoned US20180085439A1 (en) 2002-06-21 2017-11-21 Stabilised Solid Compositions of Factor VII Polypeptides
US16/164,585 Abandoned US20190111118A1 (en) 2002-06-21 2018-10-18 Stabilised Solid Compositions of Factor VII Polypeptides
US16/507,115 Abandoned US20190328851A1 (en) 2002-06-21 2019-07-10 Stabilised Solid Compositions of Factor VII Polypeptides
US16/862,623 Abandoned US20200254072A1 (en) 2002-06-21 2020-04-30 Stabilised Solid Compositions of Factor VII Polypeptides

Family Applications After (10)

Application Number Title Priority Date Filing Date
US11/526,503 Active 2024-11-16 US8299029B2 (en) 2002-06-21 2006-09-25 Stabilised solid compositions of factor VII polypeptides
US13/573,310 Expired - Lifetime US8729022B2 (en) 2002-06-21 2012-09-10 Stabilised solid compositions of factor VII polypeptides
US14/186,145 Abandoned US20140178356A1 (en) 2002-06-21 2014-02-21 Stabilised Solid Compositions of Factor VII Polypeptides
US14/823,573 Abandoned US20150343064A1 (en) 2002-06-21 2015-08-11 Stabilised Solid Compositions of Factor VII Polypeptides
US15/133,654 Abandoned US20160228553A1 (en) 2002-06-21 2016-04-20 Stabilised Solid Compositions of Factor VII Polypeptides
US15/410,342 Abandoned US20170128550A1 (en) 2002-06-21 2017-01-19 Stabilised Solid Compositions of Factor VII Polypeptides
US15/819,639 Abandoned US20180085439A1 (en) 2002-06-21 2017-11-21 Stabilised Solid Compositions of Factor VII Polypeptides
US16/164,585 Abandoned US20190111118A1 (en) 2002-06-21 2018-10-18 Stabilised Solid Compositions of Factor VII Polypeptides
US16/507,115 Abandoned US20190328851A1 (en) 2002-06-21 2019-07-10 Stabilised Solid Compositions of Factor VII Polypeptides
US16/862,623 Abandoned US20200254072A1 (en) 2002-06-21 2020-04-30 Stabilised Solid Compositions of Factor VII Polypeptides

Country Status (16)

Country Link
US (11) US20040248793A1 (es)
EP (2) EP2283856B1 (es)
JP (1) JP4648002B2 (es)
KR (2) KR20050013148A (es)
CN (2) CN1671410B (es)
AU (1) AU2003240438A1 (es)
BR (1) BRPI0311959B8 (es)
CA (1) CA2490342C (es)
DK (2) DK2283856T3 (es)
ES (2) ES2653555T3 (es)
HU (1) HUE037603T2 (es)
IL (1) IL165608A (es)
PL (1) PL207018B1 (es)
PT (2) PT1517698E (es)
RU (1) RU2366451C2 (es)
WO (1) WO2004000347A1 (es)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247607A1 (en) * 1999-11-08 2004-12-09 Novus International, Inc. Use of surfactants to stabilize oocysts
US20070197440A1 (en) * 2006-02-17 2007-08-23 Grifols, S.A. THERAPEUTIC PREPARATION OF VERY HIGH PURITY FVIIa AND METHOD FOR OBTAINING SAME
US20080064856A1 (en) * 2006-03-20 2008-03-13 Wyeth Methods for reducing protein aggregation
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008134310A1 (en) * 2007-04-26 2008-11-06 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN117860874A (zh) * 2024-03-12 2024-04-12 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
JP4648002B2 (ja) * 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
AU2011203354B2 (en) * 2003-12-19 2014-07-17 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
PT2298287T (pt) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Composições estabilizadas de polipéptidos de fator vii
EP2492261B1 (en) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20080305518A1 (en) † 2004-05-04 2008-12-11 Novo Nordisk Healthcare A/G O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
WO2006089952A1 (en) * 2005-02-24 2006-08-31 Novo Nordisk Health Care Ag Amidino-compounds por stabilizing factor vii polypeptide formulations
AU2006239117A1 (en) 2005-04-28 2006-11-02 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
US9186323B2 (en) 2007-05-02 2015-11-17 Novo Nordisk Healthcare Ag High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
CN101648012A (zh) * 2008-04-24 2010-02-17 伊玛提克斯生物技术有限公司 结合到人类白细胞抗原(hla)ⅰ类或ⅱ类分子上用作疫苗的肿瘤相关肽新制剂
DK2113253T3 (da) * 2008-04-30 2010-07-19 Immatics Biotechnologies Gmbh Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
US8778921B2 (en) 2008-10-15 2014-07-15 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
CN102441172B (zh) * 2011-12-06 2014-05-07 中国医学科学院输血研究所 高纯度凝血酶原复合物制品冷冻干燥稳定剂
NZ721597A (en) * 2013-12-24 2022-07-01 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
CN104826117B (zh) * 2015-05-05 2017-11-14 广东卫伦生物制药有限公司 用于人体血清免疫球蛋白溶液制剂的储存稳定剂
CN105424946B (zh) * 2015-07-16 2016-08-24 青岛古高生物科技有限公司 一种含迷迭香酸的凝血酶时间测定试剂
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN112138149A (zh) * 2019-06-28 2020-12-29 北京基科晟斯医药科技有限公司 重组凝血因子viii制剂
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2023245335A1 (en) * 2022-06-20 2023-12-28 Staidson (Beijing) Biopharmaceuticals Co., Ltd . Activators of coagulation factor x and formulations thereof for treating bleeding disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
US20040043933A1 (en) * 2001-12-21 2004-03-04 Hansen Birthe Lykkegaard Liquid composition of modified factor VII polypeptides

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US115590A (en) 1871-06-06 Lfxlproxeixie
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4404132A (en) * 1980-05-27 1983-09-13 Cutter Laboratories, Inc. Blood coagulation promoting product
CA1182748A (en) 1980-11-21 1985-02-19 Gerard Marx Method for synthesizing procoagulant factor viii activity
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
CA1281647C (en) 1985-11-26 1991-03-19 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
AU607927B2 (en) 1986-06-24 1991-03-21 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
DE3877529T2 (de) * 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
CA1329760C (en) 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
WO1991011514A1 (en) * 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
EP1479395A1 (en) 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
JP3155797B2 (ja) 1991-12-26 2001-04-16 株式会社日立製作所 過電圧自己保護型半導体装置、及び、それを使用した半導体回路
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
AU678987B2 (en) 1992-08-27 1997-06-19 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
HU219682B (hu) 1993-05-21 2001-06-28 Novo Nordisk A/S. Módosított VII faktor
AU7254894A (en) 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5576291A (en) 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) 1994-11-14 1994-11-14 Annelie Almstedt Process A
US5649959A (en) 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SE9503679D0 (sv) 1995-10-20 1995-10-20 Pharmacia Ab Antioxidants
AU7068896A (en) 1995-11-09 1997-05-15 Corunum Corporation Protein composition derived from sesame seed and use thereof
US6320029B1 (en) 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
DE19903693A1 (de) 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE270899T1 (de) 1996-12-24 2004-07-15 Biogen Inc Stabile flüssige interferon-zubereitungen
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1998048822A1 (en) 1997-04-28 1998-11-05 Eli Lilly And Company Improved methods for processing activated protein c
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
RU2142278C1 (ru) * 1997-10-31 1999-12-10 Чухаджян Ара Гарникович Гемостатическое средство местного действия
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU1311800A (en) 1998-10-07 2000-04-26 Sigma-Aldrich Co. Thromboplastin reagents and methods for preparing and using such reagents
DE19853033A1 (de) 1998-11-18 2000-05-25 Centeon Pharma Gmbh Stabilisierte Proteinzubereitung für einen Gewebekleber
US6586573B1 (en) * 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
ATE310533T1 (de) 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
EP1210361B1 (en) † 1999-08-17 2004-04-14 Novo Nordisk Health Care AG Stabilisation of freeze-dried cake
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
DE60038386T2 (de) 1999-09-08 2009-04-23 Chugai Seiyaku K.K. Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
US6750053B1 (en) * 1999-11-15 2004-06-15 I-Stat Corporation Apparatus and method for assaying coagulation in fluid samples
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
ES2449224T3 (es) * 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Administración subcutánea del Factor de coagulación VII
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
PL365042A1 (en) 2000-05-10 2004-12-27 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
RU2325181C2 (ru) * 2000-10-02 2008-05-27 Ново Нордиск Хелт Кэр Аг Гликоформы фактора vii
CA2422214A1 (en) * 2000-10-02 2002-04-11 Novo Nordisk A/S Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
EP1226829B1 (de) * 2001-01-08 2008-06-11 CSL Behring GmbH Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
JP2004529640A (ja) 2001-03-22 2004-09-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ凝固因子誘導体
CA2452395C (en) 2001-07-10 2012-04-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Pharmaceutically stable hemostatic compositions
GB0117879D0 (en) 2001-07-21 2001-09-12 Common Services Agency Storage of liquid compositions
US6858587B2 (en) * 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
DE60332604D1 (de) 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
ES2377959T3 (es) † 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
US6933808B2 (en) 2002-07-17 2005-08-23 Qing Ma Microelectromechanical apparatus and methods for surface acoustic wave switching
EP1422309A1 (de) 2002-11-22 2004-05-26 Siemens Aktiengesellschaft Verwendung einer Sprühkompaktierungsanlage zur Erzeugung einer Schicht und Schichtsystem hergestellt mittels einer Sprühkompaktierungsanlage und Schichtsystem
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
RU2005132164A (ru) * 2003-03-18 2006-06-10 Ново Нордиск Хелт Кэр Аг (Ch) Жидкие, водные фармацевтические композиции полипептидов фактора vii
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1628677B1 (en) * 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
EP1646398A2 (en) 2003-06-13 2006-04-19 Novo Nordisk Health Care AG Formulations comprising factor viia and a factor vii related polypeptide
ATE446768T1 (de) 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
PT2298287T (pt) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Composições estabilizadas de polipéptidos de fator vii
AU2006239117A1 (en) 2005-04-28 2006-11-02 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
US4784950A (en) * 1985-04-17 1988-11-15 Zymogenetics, Inc. Expression of factor VII activity in mammalian cells
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US20040043933A1 (en) * 2001-12-21 2004-03-04 Hansen Birthe Lykkegaard Liquid composition of modified factor VII polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247607A1 (en) * 1999-11-08 2004-12-09 Novus International, Inc. Use of surfactants to stabilize oocysts
US20070197440A1 (en) * 2006-02-17 2007-08-23 Grifols, S.A. THERAPEUTIC PREPARATION OF VERY HIGH PURITY FVIIa AND METHOD FOR OBTAINING SAME
US7531513B2 (en) * 2006-02-17 2009-05-12 Grifols, S.A. Therapeutic preparation of very high purity FVIIa and method for obtaining same
US20080064856A1 (en) * 2006-03-20 2008-03-13 Wyeth Methods for reducing protein aggregation
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008078189A3 (en) * 2006-12-20 2009-03-05 Bayer Healthcare Llc Factor vii and viia compositions
WO2008134310A1 (en) * 2007-04-26 2008-11-06 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US20100113744A1 (en) * 2007-04-26 2010-05-06 Bayer Healthcare Llc Stabilization Of Liquid Solutions Of Recombinant Protein For Frozen Storage
US8187799B2 (en) 2007-04-26 2012-05-29 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US8536125B2 (en) 2007-04-26 2013-09-17 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN117860874A (zh) * 2024-03-12 2024-04-12 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Also Published As

Publication number Publication date
EP1517698B1 (en) 2014-08-13
EP2283856B1 (en) 2017-09-20
DK2283856T3 (da) 2017-11-20
RU2005101340A (ru) 2005-12-10
RU2366451C2 (ru) 2009-09-10
US20140178356A1 (en) 2014-06-26
AU2003240438A1 (en) 2004-01-06
ES2653555T3 (es) 2018-02-07
EP2283856A1 (en) 2011-02-16
IL165608A (en) 2011-04-28
ES2523655T5 (es) 2018-04-23
KR101212025B1 (ko) 2013-01-09
BR0311959A (pt) 2005-04-26
DK1517698T4 (da) 2018-01-29
EP1517698A1 (en) 2005-03-30
US20170128550A1 (en) 2017-05-11
CN1671410A (zh) 2005-09-21
PL207018B1 (pl) 2010-10-29
PT1517698E (pt) 2014-11-19
BRPI0311959B1 (pt) 2021-01-05
CN101912601A (zh) 2010-12-15
CN1671410B (zh) 2010-05-12
US8729022B2 (en) 2014-05-20
US20160228553A1 (en) 2016-08-11
CN101912601B (zh) 2012-08-29
DK1517698T3 (en) 2014-11-24
US20070207956A1 (en) 2007-09-06
EP1517698B2 (en) 2017-12-06
BRPI0311959B8 (pt) 2021-05-25
PL373904A1 (en) 2005-09-19
JP4648002B2 (ja) 2011-03-09
ES2523655T3 (es) 2014-11-28
IL165608A0 (en) 2006-01-15
KR20050013148A (ko) 2005-02-02
US20190328851A1 (en) 2019-10-31
JP2006513983A (ja) 2006-04-27
KR20110049897A (ko) 2011-05-12
HUE037603T2 (hu) 2018-09-28
US20150343064A1 (en) 2015-12-03
PT2283856T (pt) 2017-12-26
US20130017184A1 (en) 2013-01-17
WO2004000347A1 (en) 2003-12-31
CA2490342C (en) 2015-06-16
US20200254072A1 (en) 2020-08-13
CA2490342A1 (en) 2003-12-31
US8299029B2 (en) 2012-10-30
US20180085439A1 (en) 2018-03-29
US20190111118A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US20200254072A1 (en) Stabilised Solid Compositions of Factor VII Polypeptides
US20220054604A1 (en) Stabilised Compositions of Factor VII Polypeptides
AU2011203354B2 (en) Stabilised compositions of factor VII polypeptides

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK HEALTHCARE A/G, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JENSEN, MICHAEL BECH;HANSEN, BIRTHE LYKKEGAARD;KORNFELT, TROELS;REEL/FRAME:017170/0675;SIGNING DATES FROM 20050711 TO 20050804

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION